Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPS6159624B2 - - Google Patents
[go: Go Back, main page]

JPS6159624B2 - - Google Patents

Info

Publication number
JPS6159624B2
JPS6159624B2 JP55163123A JP16312380A JPS6159624B2 JP S6159624 B2 JPS6159624 B2 JP S6159624B2 JP 55163123 A JP55163123 A JP 55163123A JP 16312380 A JP16312380 A JP 16312380A JP S6159624 B2 JPS6159624 B2 JP S6159624B2
Authority
JP
Japan
Prior art keywords
mol
methyl
group
ether
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP55163123A
Other languages
Japanese (ja)
Other versions
JPS5788160A (en
Inventor
Hajime Fujimura
Yasuzo Hiramatsu
Takahiro Yabuchi
Masakatsu Kuki
Katsuo Takigawa
Takatsugu Pponna
Hidekazu Myake
Akira Kajitani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Priority to JP16312380A priority Critical patent/JPS5788160A/en
Publication of JPS5788160A publication Critical patent/JPS5788160A/en
Publication of JPS6159624B2 publication Critical patent/JPS6159624B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

【発明の詳細な説明】 本発明は新規な1,2,5−置換イソビウレツ
ト化合物に関するものである。 本発明に係る1,2,5−置換イソビウレツト
化合物は一般式 (式中、R1はフエニル基又は置換基として低
級アルキル基、低級アルコキシ基を有するフエニ
ル基を、R2およびR3は低級アルキル基を意味す
る)で表わされる。 上記一般式()で示される1,2,5−置換
イソビウレツト化合物のR1〜R3において、低級
アルキル基としては、炭素数1〜6の鎖状あるい
は分枝状のアルキル基、例えば、メチル、エチ
ル、プロピル、イソプロピル、ブチル、ペンチ
ル、ヘキシル基等を、フエニル基の置換基である
低級アルコキシ基としては、炭素数1〜6のアル
コキシ基、例えば、メトキシ、エトキシ、プロポ
キシ、ブトキシ、ペンチルオキシ、ヘキシルオキ
シ基等を挙げることができる。 本発明の1,2,5−置換イソビウレツト化合
物は文献未載の新規化合物であつて、抗炎症作
用、鎮痛作用、抗アレルギー作用、利尿作用、抗
菌作用および抗痙れん作用を有する有用な化合物
である。 本発明に係る1,2,5−置換イソビウレツト
化合物は、例えば次の反応式で示されるように、
一般式()で示されるイソ尿素と一般式()
で示されるイソシアナートを反応させることによ
り合成される。 (式中、R1,R2及びR3は前記と同一の意味を
有する) 一般式()で示されるイソ尿素と一般式
()で示されるイソシアナートはいずれも公知
化合物であり、その反応は通常溶媒中あるいは無
溶媒下で行われる。溶媒としては反応に関与しな
いものである限り特に限定されないが、一般にエ
ーテル、ジオキサン、テトラヒドロフラン等のエ
ーテル類、ベンゼン、トルエン、キシレン等の芳
香族炭化水素類、クロロホルム、ジクロルメタ
ン、ジクロルエタン等のハロゲノアルカン類等が
好ましい。 一般式()で示されるイソ尿素と一般式
()で示されるイソシアナートの使用割合は適
宜選択すれば良いが、一般に等モル量程度使用す
るのが有利である。反応温度も適宜選択すれば良
いが、一般に−20℃〜使用する溶媒の沸点の温度
範囲において反応は有利に進行する。 尚、本発明化合物は通常公知の分離手段、例え
ば抽出、カラムクロマトグラフイー、再結晶等の
手段により容易に分離精製される。 以下本発明の実施例を示す。 実施例 1 2−メチル−1−フエニルイソ尿素6g(0.04
モル)をエーテル60mlに溶解し、氷冷撹拌下、メ
チルイソシアナート2.3g(0.04モル)を加え、
室温にて2時間撹拌した後、溶媒を留去し、残渣
をベンゼンより再結晶すると融点91〜93℃の2,
5−ジメチル−1−フエニル−2−イソビウレツ
ト7.6g(92%)が得られる。 元素分析値(C10H13N3O2として) 計算値(%) C57.96 H6.32 N20.28 実測値(%) C57.83 H6.00 N19.98 実施例 2 2−メチル−1−(4−メチルフエニル)イソ
尿素6.6g(0.04モル)をエーテル60mlに溶解
し、氷冷撹拌下メチルイソシアナート2.3g
(0.04モル)を加え、室温にて2時間撹拌した
後、溶媒を留去し、残渣をベンゼン−石油エーテ
ルより再結晶すると融点89〜92℃の2,5−ジメ
チル−1−(4−メチルフエニル)−2−イソビウ
レツト6.2g(70%)が得られる。 元素分析値(C11H15N3O2として) 計算値(%) C59.71 H6.83 N18.99 実測値(%) C59.61 H6.73 N18.89 実施例 3 1−(4−メトキシフエニル)−2−メチルイソ
尿素7.2g(0.04モル)をエーテル60mlに溶解
し、氷冷撹拌下、メチルイソシアナート2.3g
(0.04モル)を加え、室温にて2時間撹拌した
後、溶媒を留去し、残渣をエーテルより再結晶す
ると融点77〜78℃の1−(4−メトキシフエニ
ル)−2,5−ジメチル−2−イソビウレツト6.5
g(68%)が得られる。 元素分析値(C11H15N3O3として) 計算値(%) C55.69 H6.37 N17.71 実測値(%) C55.44 H6.26 N17.52 実施例 4 2−メチル−1−フエニルイソ尿素6g(0.04
モル)をエーテル60mlに溶解し、氷冷撹拌下、エ
チルイソシアナート2.8g(0.04モル)を加え、
室温にて2時間撹拌した後、析出した結晶を取
し、ヘキサンより再結晶すると融点57〜59℃の5
−エチル−2−メチル−1−フエニル−2−イソ
ビウレツト7g(80%)が得られる。 元素分析値(C11H15N3O2として) 計算値(%) C59.71 H6.83 N18.99 実測値(%) C59.62 H6.59 N18.98 実施例 5 2−メチル−1−フエニルイソ尿素2.8g
(0.019モル)をエーテル30mlに溶解し、氷冷撹拌
下、プロピルイソシアナート1.6g(0.019モル)
を加え、室温にて2時間撹拌した後、溶媒を減圧
下留去し、残渣をヘキサンより再結晶すると融点
38〜41℃の2−メチル−1−フエニル−5−プロ
ピル−2−イソビウレツト3.3g(75%)が得ら
れる。 元素分析値(C12H17N3O2として) 計算値(%) C61.26 H7.28 N17.86 実測値(%) C61.36 H7.06 N17.99 実施例 6 2−メチル−1−フエニルイソ尿素6g(0.04
モル)をエーテル60mlに溶解し、氷冷撹拌下、ブ
チルイソシアナート4g(0.04モル)を加え、室
温にて2時間撹拌した後、溶媒を減圧下留去し、
残渣をヘキサンより再結晶すると融点53〜56℃の
5−ブチル−2−メチル−1−フエニル−2−イ
ソビウレツト8.6g(86%)が得られる。 元素分析値(C13H19N3O2として) 計算値(%) C62.63 H7.68 N16.85 実測値(%) C62.63 H7.81 N16.63 次に本発明化合物の鎮痛作用および急性毒性を
下記の試験方法により測定し、その結果を第1表
に示す。 鎮痛作用 1 酢酸ストレツチング法 Kosterらの方法〔Federation Proceedings
18,412(1959)〕に従つて、ddy系雄性マウス
(体重20〜25g)各群6〜8匹を用い、一夜絶食
後、薬物100mg/Kgを経口投与した1時間後に、
0.7%酢酸を動物一匹あたり0.2mlずつ腹腔内投与
し、ストレツチング症状を観察して抑制率(%)
を求めた。 2 ハフナー変法 藤村らの変法〔京都大学化学研究所報告第25
集、36(1951)〕に従つて、ddy系雄性マウス
(体重20〜25g)各群6〜8匹を用い、一夜絶食
後、薬物100mg/Kgを経口投与した45分後に、閾
値用量の塩酸モルヒネ(1.5〜2.5mg/Kg)を皮下
注射し、以後1時間のクレンメによる疼通反応を
観察し、抑制率(%)を求めた。 急性毒性試験 ddy系雄性マウス(体重20〜25g)を用い、一
夜絶食後、薬物を経口投与した。投与後の一般症
状は7日間観察し、投与量(mg/Kg)に対する死
亡率/一群動物数として表わした。 以上の試験において、薬物はすべて0.25%カル
ボキシメチルセルロース液中に懸濁して用いた。 【表】
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to novel 1,2,5-substituted isobiuret compounds. The 1,2,5-substituted isobiuret compound according to the present invention has the general formula (In the formula, R 1 is a phenyl group or a phenyl group having a lower alkyl group or lower alkoxy group as a substituent, and R 2 and R 3 are lower alkyl groups.) In R 1 to R 3 of the 1,2,5-substituted isobiureth compound represented by the above general formula (), the lower alkyl group is a chain or branched alkyl group having 1 to 6 carbon atoms, such as methyl , ethyl, propyl, isopropyl, butyl, pentyl, hexyl, etc., and as a lower alkoxy group which is a substituent of a phenyl group, an alkoxy group having 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, butoxy, pentyloxy , hexyloxy group, etc. The 1,2,5-substituted isobiuret compound of the present invention is a new compound that has not been described in any literature, and is a useful compound having anti-inflammatory, analgesic, antiallergic, diuretic, antibacterial, and antispasmodic effects. be. The 1,2,5-substituted isobiuret compound according to the present invention is, for example, as shown in the following reaction formula,
Isourea shown by general formula () and general formula ()
It is synthesized by reacting isocyanates shown in (In the formula, R 1 , R 2 and R 3 have the same meanings as above.) The isourea represented by the general formula () and the isocyanate represented by the general formula () are both known compounds, and their reaction is usually carried out in a solvent or without a solvent. The solvent is not particularly limited as long as it does not participate in the reaction, but generally includes ethers such as ether, dioxane, and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene, and xylene, and halogenoalkanes such as chloroform, dichloromethane, and dichloroethane. etc. are preferred. The ratio of the isourea represented by the general formula () and the isocyanate represented by the general formula () may be appropriately selected, but it is generally advantageous to use equimolar amounts. Although the reaction temperature may be selected appropriately, the reaction generally proceeds advantageously within a temperature range of -20°C to the boiling point of the solvent used. The compound of the present invention can be easily separated and purified by commonly known separation means such as extraction, column chromatography, and recrystallization. Examples of the present invention will be shown below. Example 1 6 g of 2-methyl-1-phenylisourea (0.04
mol) in 60 ml of ether, add 2.3 g (0.04 mol) of methyl isocyanate while stirring under ice cooling,
After stirring at room temperature for 2 hours, the solvent was distilled off and the residue was recrystallized from benzene to give 2,
7.6 g (92%) of 5-dimethyl-1-phenyl-2-isobiuret are obtained. Elemental analysis value (as C 10 H 13 N 3 O 2 ) Calculated value (%) C57.96 H6.32 N20.28 Actual value (%) C57.83 H6.00 N19.98 Example 2 2-Methyl-1 - Dissolve 6.6 g (0.04 mol) of (4-methylphenyl)isourea in 60 ml of ether, and add 2.3 g of methyl isocyanate while stirring on ice.
(0.04 mol) and stirred at room temperature for 2 hours, the solvent was distilled off and the residue was recrystallized from benzene-petroleum ether to give 2,5-dimethyl-1-(4-methylphenyl) with a melting point of 89-92°C. )-2-isobiuret 6.2 g (70%) are obtained. Elemental analysis value (as C 11 H 15 N 3 O 2 ) Calculated value (%) C59.71 H6.83 N18.99 Actual value (%) C59.61 H6.73 N18.89 Example 3 1-(4- 7.2 g (0.04 mol) of methoxyphenyl)-2-methylisourea was dissolved in 60 ml of ether, and 2.3 g of methyl isocyanate was dissolved under stirring under ice cooling.
(0.04 mol) and stirred at room temperature for 2 hours, the solvent was distilled off and the residue was recrystallized from ether to yield 1-(4-methoxyphenyl)-2,5-dimethyl with a melting point of 77-78°C. -2-isobiuret 6.5
g (68%) is obtained. Elemental analysis value (as C 11 H 15 N 3 O 3 ) Calculated value (%) C55.69 H6.37 N17.71 Actual value (%) C55.44 H6.26 N17.52 Example 4 2-Methyl-1 - Phenyl isourea 6g (0.04
mol) in 60 ml of ether, add 2.8 g (0.04 mol) of ethyl isocyanate under ice-cooling and stirring,
After stirring at room temperature for 2 hours, the precipitated crystals were collected and recrystallized from hexane to give 5.
7 g (80%) of -ethyl-2-methyl-1-phenyl-2-isobiureth are obtained. Elemental analysis value (as C 11 H 15 N 3 O 2 ) Calculated value (%) C59.71 H6.83 N18.99 Actual value (%) C59.62 H6.59 N18.98 Example 5 2-Methyl-1 -Phenylisourea 2.8g
(0.019 mol) was dissolved in 30 ml of ether, and while stirring under ice cooling, 1.6 g (0.019 mol) of propyl isocyanate was dissolved.
After stirring at room temperature for 2 hours, the solvent was distilled off under reduced pressure and the residue was recrystallized from hexane.
3.3 g (75%) of 2-methyl-1-phenyl-5-propyl-2-isobiuret at 38-41 DEG C. are obtained. Elemental analysis value (as C 12 H 17 N 3 O 2 ) Calculated value (%) C61.26 H7.28 N17.86 Actual value (%) C61.36 H7.06 N17.99 Example 6 2-Methyl-1 - Phenyl isourea 6g (0.04
mol) was dissolved in 60 ml of ether, 4 g (0.04 mol) of butyl isocyanate was added under stirring under ice-cooling, and after stirring at room temperature for 2 hours, the solvent was distilled off under reduced pressure.
Recrystallization of the residue from hexane yields 8.6 g (86%) of 5-butyl-2-methyl-1-phenyl-2-isobiureth having a melting point of 53 DEG -56 DEG C. Elemental analysis value (as C 13 H 19 N 3 O 2 ) Calculated value (%) C62.63 H7.68 N16.85 Actual value (%) C62.63 H7.81 N16.63 Next, the analgesic effect of the compound of the present invention and acute toxicity were measured by the following test methods, and the results are shown in Table 1. Analgesic effect 1 Acetic acid stretching method Koster et al.'s method [Federation Proceedings
18 , 412 (1959)], using 6 to 8 DDY male mice (body weight 20 to 25 g) in each group, after an overnight fast, 1 hour after oral administration of 100 mg/Kg of the drug,
Administer 0.2ml of 0.7% acetic acid intraperitoneally per animal, observe the stretching symptoms, and calculate the suppression rate (%).
I asked for 2 Modified Hafner method Modified method of Fujimura et al. [Kyoto University Chemical Research Institute Report No. 25]
36 (1951)], 6 to 8 male DDY mice (body weight 20 to 25 g) were used in each group, and after an overnight fast, 45 minutes after orally administering 100 mg/Kg of the drug, a threshold dose of hydrochloric acid was administered. Morphine (1.5 to 2.5 mg/Kg) was injected subcutaneously, and the pain response caused by the cream was observed for 1 hour thereafter to determine the inhibition rate (%). Acute Toxicity Test The drug was orally administered to male DDY mice (body weight 20-25 g) after an overnight fast. General symptoms after administration were observed for 7 days and expressed as mortality rate/number of animals per group relative to dose (mg/Kg). In the above tests, all drugs were suspended in 0.25% carboxymethyl cellulose solution. 【table】

Claims (1)

【特許請求の範囲】 1 一般式 (式中R1はフエニル基又は置換基として低級
アルキル基、低級アルコキシ基を有するフエニル
基を、R2およびR3は低級アルキル基を意味す
る)で示される1,2,5−置換イソビウレツト
化合物。
[Claims] 1. General formula (In the formula, R 1 is a phenyl group or a phenyl group having a lower alkyl group or a lower alkoxy group as a substituent, and R 2 and R 3 are lower alkyl groups.) .
JP16312380A 1980-11-18 1980-11-18 1,2,5-substituted isobiuret compound Granted JPS5788160A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP16312380A JPS5788160A (en) 1980-11-18 1980-11-18 1,2,5-substituted isobiuret compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16312380A JPS5788160A (en) 1980-11-18 1980-11-18 1,2,5-substituted isobiuret compound

Publications (2)

Publication Number Publication Date
JPS5788160A JPS5788160A (en) 1982-06-01
JPS6159624B2 true JPS6159624B2 (en) 1986-12-17

Family

ID=15767612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP16312380A Granted JPS5788160A (en) 1980-11-18 1980-11-18 1,2,5-substituted isobiuret compound

Country Status (1)

Country Link
JP (1) JPS5788160A (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788704A (en) * 1971-09-16 1973-01-02 Du Pont USEFUL ALLOPHANIMIDATES AS HERBICIDES

Also Published As

Publication number Publication date
JPS5788160A (en) 1982-06-01

Similar Documents

Publication Publication Date Title
CA1336913C (en) Saturated fatty acid amides as inhibitors of acyl-coa:cholesterol acyltransferase
JPH0133470B2 (en)
US3995039A (en) Pyrazolo [1,5-a] [1,3,5] triazines
JPS6089474A (en) Morphinan derivative, production thereof and antitumor agent containing said compound
KR850000216B1 (en) Method for preparing piperazine derivatives
JPH026354B2 (en)
KR870000545B1 (en) Process for the preparation of dihydroxy benzamide derivative
KR840001131B1 (en) Process for preparing substituted -oxo- -phenyl-carbamoyl-pyrrol propionitriles
EP0057881B1 (en) An anti-inflammatory, analgesic, and antipyretic pharmaceutical composition, and method for producing it
US4190659A (en) Pharmaceutical preparation and use of 4-hydroxy-2-quinolinone-3-carboxylic acid esters
EP0093945B1 (en) 1,4-dihydropyridine derivatives
JPH0370698B2 (en)
JPS6159624B2 (en)
CA1040640A (en) Indazole-3-carboxylic acid hydrazides and a process for the preparation thereof
JPH0710863B2 (en) Novel derivative of 4-OH quinolinecarboxylic acid substituted at position 2 with an etherifiable or esterifiable dihydroxy group, a process for its preparation and its use as a medicament
JPS6223747B2 (en)
US4093627A (en) 3-[(4-Chromanylidene)amino]-2-oxazolidinones
JPH0370700B2 (en)
US3991082A (en) 4-Substituted-2,3-dihydro-1-benzoxepin-3,5-diones and tautomers
EP0090275A2 (en) Isoxazole (5,4-b) pyridines
JPS6154784B2 (en)
EP0045473A1 (en) A pharmaceutical composition containing a benzofuran-carboxamide derivative as the active ingredient
EP0197533B1 (en) Dioxolobenzisoxazole derivatives and process for preparing the same
US4007207A (en) Alkyl substituted-4-oxo-cyclopenta benzopyrans
US3974145A (en) Novel N'-acylated phenyl-hydrazine and hydrozone derivatives